• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hemophilia A - Pipeline Review, H1 2014 - Product Image

Hemophilia A - Pipeline Review, H1 2014

  • Published: February 2014
  • 174 pages
  • Global Markets Direct

FEATURED COMPANIES

  • AlphaMab Co., Ltd
  • AstraZeneca PLC
  • Biogen Idec Inc.
  • EpiVax, Inc.
  • Inserm Transfert SA
  • Octapharma AG
  • MORE

Hemophilia A - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Hemophilia A - Pipeline Review, H1 2014’, provides an overview of the Hemophilia A’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records READ MORE >

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Hemophilia A Overview
Therapeutics Development
Pipeline Products for Hemophilia A - Overview
Pipeline Products for Hemophilia A - Comparative Analysis
Hemophilia A - Therapeutics under Development by Companies
Hemophilia A - Therapeutics under Investigation by Universities/Institutes
Hemophilia A - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Hemophilia A - Products under Development by Companies
Hemophilia A - Products under Investigation by Universities/Institutes
Hemophilia A - Companies Involved in Therapeutics Development
Baxter International Inc.
Biogen Idec Inc.
AstraZeneca PLC
Cangene Corporation
Lentigen Corporation
Sangamo BioSciences, Inc.
Pharming Group N.V.
Novo Nordisk A/S
Grifols, S.A.
BioMarin Pharmaceutical Inc.
Chugai Pharmaceutical Co., Ltd.
rEVO Biologics
Octapharma AG
Pfizer Inc.
Bayer AG
Prolor Biotech, Inc.
ReGenX Biosciences, LLC
Alnylam Pharmaceuticals, Inc.
CSL Limited
Green Cross Corporation
Amarna Therapeutics B.V.
EpiVax, Inc.
Expression Therapeutics LLC
Asklepios BioPharmaceutical, Inc.
Amunix, Inc.
Inserm Transfert SA
Selecta Biosciences, Inc.
Celtic Pharmaceutical Holdings L.P.
Inbiopro Solutions Pvt. Ltd.
International Biotechnology Center Generium
AlphaMab Co., Ltd
Dong-A Socio Holdings Co Ltd
Hemophilia A - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
turoctocog alfa - Drug Profile
antihemophilic factor-Fc (recombinant) - Drug Profile
OBI-1 - Drug Profile
hcl-rFVIII - Drug Profile
GNR-001 - Drug Profile
antihemophilic factor-Fc (recombinant) - Drug Profile
OBI-1 - Drug Profile
BAX-855 - Drug Profile
hcl-rFVIII - Drug Profile
BAY-818973 - Drug Profile
NN-7088 - Drug Profile
BAY-949027 - Drug Profile
LR-769 - Drug Profile
CSL-627 - Drug Profile
beroctocog alfa - Drug Profile
BAX-817 - Drug Profile
GNR-002 - Drug Profile
oprelvekin - Drug Profile
ACE-910 - Drug Profile
CSL-689 - Drug Profile
PF-05280602 - Drug Profile
concizumab - Drug Profile
MOD-5017 - Drug Profile
ALN-AT3 - Drug Profile
eptacog alfa biosimilar - Drug Profile
ZFP Nucleases For Hemophilia - Drug Profile
LG-889 - Drug Profile
IB1-007 - Drug Profile
IB1-008 - Drug Profile
DA-3808 - Drug Profile
PEG-rFVIII-PI Complex - Drug Profile
Human Coagulation Factor-VIII - Drug Profile
Deimmunized FVIII - Drug Profile
Gene Therapy To Activate Factor VIII For Hemophilia A - Drug Profile
Factor VIII Program - Drug Profile
Long Acting Coagulation Factor VIIa - Drug Profile
Gene Therapy For Hemophilia A - Drug Profile
SEL-201 - Drug Profile
Factor VIII Gene Therapy Program - Drug Profile
TheraPEG-FVIII - Drug Profile
moroctocog alfa biosimilar - Drug Profile
Lentiviral Based Gene Therapy - Drug Profile
beroctocog alfa - Drug Profile
LG-888 - Drug Profile
rhFactor VIII - Drug Profile
BNP-FVIII - Drug Profile
AZ-10047130 - Drug Profile
AZ-10214075 - Drug Profile
AZ-10776241 - Drug Profile
Gene Therapy For Hemophilia A - Drug Profile
IBPH-001-OC - Drug Profile
beroctocog alfa - Drug Profile
SVF-VIIa - Drug Profile
Hemophilia A - Recent Pipeline Updates
Hemophilia A - Dormant Projects
Hemophilia A - Discontinued Products
Hemophilia A - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hemophilia A, H1 2014
Number of Products under Development for Hemophilia A - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Development by Companies, H1 2014 (Contd..1)
Number of Products under Development by Companies, H1 2014 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Comparative Analysis by Unknown Stage Development, H1 2014
Products under Development by Companies, H1 2014
Products under Development by Companies, H1 2014 (Contd..1)
Products under Development by Companies, H1 2014 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2014
Hemophilia A - Pipeline by Baxter International Inc., H1 2014
Hemophilia A - Pipeline by Biogen Idec Inc., H1 2014
Hemophilia A - Pipeline by AstraZeneca PLC, H1 2014
Hemophilia A - Pipeline by Cangene Corporation, H1 2014
Hemophilia A - Pipeline by Lentigen Corporation, H1 2014
Hemophilia A - Pipeline by Sangamo BioSciences, Inc., H1 2014
Hemophilia A - Pipeline by Pharming Group N.V., H1 2014
Hemophilia A - Pipeline by Novo Nordisk A/S, H1 2014
Hemophilia A - Pipeline by Grifols, S.A., H1 2014
Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc., H1 2014
Hemophilia A - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014
Hemophilia A - Pipeline by rEVO Biologics, H1 2014
Hemophilia A - Pipeline by Octapharma AG, H1 2014
Hemophilia A - Pipeline by Pfizer Inc., H1 2014
Hemophilia A - Pipeline by Bayer AG, H1 2014
Hemophilia A - Pipeline by Prolor Biotech, Inc., H1 2014
Hemophilia A - Pipeline by ReGenX Biosciences, LLC, H1 2014
Hemophilia A - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2014
Hemophilia A - Pipeline by CSL Limited, H1 2014
Hemophilia A - Pipeline by Green Cross Corporation, H1 2014
Hemophilia A - Pipeline by Amarna Therapeutics B.V., H1 2014
Hemophilia A - Pipeline by EpiVax, Inc., H1 2014
Hemophilia A - Pipeline by Expression Therapeutics LLC, H1 2014
Hemophilia A - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2014
Hemophilia A - Pipeline by Amunix, Inc., H1 2014
Hemophilia A - Pipeline by Inserm Transfert SA, H1 2014
Hemophilia A - Pipeline by Selecta Biosciences, Inc., H1 2014
Hemophilia A - Pipeline by Celtic Pharmaceutical Holdings L.P., H1 2014
Hemophilia A - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014
Hemophilia A - Pipeline by International Biotechnology Center Generium, H1 2014
Hemophilia A - Pipeline by AlphaMab Co., Ltd, H1 2014
Hemophilia A - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014
Assessment by Monotherapy Products, H1 2014
Number of Products by Stage and Target, H1 2014
Number of Products by Stage and Mechanism of Action, H1 2014
Number of Products by Stage and Route of Administration, H1 2014
Number of Products by Stage and Molecule Type, H1 2014
Hemophilia A Therapeutics - Recent Pipeline Updates, H1 2014
Hemophilia A - Dormant Projects, H1 2014
Hemophilia A - Discontinued Products, H1 2014

List of Figures
Number of Products under Development for Hemophilia A, H1 2014
Number of Products under Development for Hemophilia A - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Products, H1 2014
Assessment by Monotherapy Products, H1 2014
Number of Products by Top 10 Target, H1 2014
Number of Products by Stage and Top 10 Target, H1 2014
Number of Products by Top 10 Mechanism of Action, H1 2014
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
Number of Products by Top 10 Route of Administration, H1 2014
Number of Products by Stage and Top 10 Route of Administration, H1 2014
Number of Products by Top 10 Molecule Type, H1 2014
Number of Products by Stage and Top 10 Molecule Type, H1 2014 70

Baxter International Inc.
Biogen Idec Inc.
AstraZeneca PLC
Cangene Corporation
Lentigen Corporation
Sangamo BioSciences, Inc.
Pharming Group N.V.
Novo Nordisk A/S
Grifols, S.A.
BioMarin Pharmaceutical Inc.
Chugai Pharmaceutical Co., Ltd.
rEVO Biologics
Octapharma AG
Pfizer Inc.
Bayer AG
Prolor Biotech, Inc.
ReGenX Biosciences, LLC
Alnylam Pharmaceuticals, Inc.
CSL Limited
Green Cross Corporation
Amarna Therapeutics B.V.
EpiVax, Inc.
Expression Therapeutics LLC
Asklepios BioPharmaceutical, Inc.
Amunix, Inc.
Inserm Transfert SA
Selecta Biosciences, Inc.
Celtic Pharmaceutical Holdings L.P.
Inbiopro Solutions Pvt. Ltd.
International Biotechnology Center Generium
AlphaMab Co., Ltd
Dong-A Socio Holdings Co Ltd

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos